The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

Sunkyu Kim, Ralph Tiedt, Alice Loo, Thomas Horn, Scott Delach, Steven Kovats, Kristy Haas, Barbara Schacher Engstler, Alexander Cao, Maria Pinzon-Ortiz, Iain J. Mulford, Michael Acker, Rajiv Chopra, Christopher T. Brain, Emmanuelle di Tomaso, William R. Sellers, Giordano CaponigroOncotarget 2018 · DOI

Abstract

Inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) is associated with robust antitumor activity. Ribociclib (LEE011) is an orally bioavailable CDK4/6 inhibitor that is approved for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer, in combination with an aromatase inhibitor, and is currently being evaluated in several additional trials. Here, we report the preclinical profile of ribociclib. When tested across a large panel of kinase active site binding assays, ribociclib and palbociclib were highly selective for CDK4, while abemaciclib showed affinity to several other kinases. Both ribociclib and abemaciclib showed slightly higher potency in CDK4-dependent cells than in CDK6-dependent cells, while palbociclib did not show such a difference. Profiling CDK4/6 inhibitors in large-scale cancer cell line screens in vitro confirmed that RB1 loss of function is a negative predictor of sensitivity. We also found that routinely used cellular viability assays measuring adenosine triphosphate levels as a proxy for cell numbers underestimated the effects of CDK4/6 inhibition, which contrasts with assays that assess cell number more directly. Robust antitumor efficacy and combination benefit was detected when ribociclib was added to encorafenib, nazartinib, or endocrine therapies in patient-derived xenografts.

Introduction

The cell cycle transition from G1 to S phase is a critical checkpoint often dysregulated in cancer. Cyclin-dependent kinases 4 and 6 (CDK4/6) drive this transition, making them prime therapeutic targets. While several CDK4/6 inhibitors are clinically available, understanding their biochemical nuances—selectivity, potency across lineages, and optimal combination strategies—is essential for maximizing clinical benefit. This study provides a comprehensive preclinical characterization of ribociclib (LEE011), highlighting its selectivity and identifying critical factors for accurate efficacy assessment.

Kinome Selectivity and Potency

A key differentiator among CDK4/6 inhibitors is their selectivity across the kinome. Using the KINOMEscan platform to test binding affinity against over 465 kinases, the researchers compared ribociclib, palbociclib, and abemaciclib.

Kinome selectivity profiles of ribociclib, palbociclib, and abemaciclib.

Ribociclib and palbociclib demonstrated high selectivity for CDK4/6 with minimal "off-target" binding. In contrast, abemaciclib showed affinity for several other kinases even at low concentrations. Furthermore, ribociclib exhibited a lineage preference, showing significantly higher potency in CDK4-dependent lines (typical of epithelial tumors like breast cancer) compared to CDK6-dependent lines (common in hematological malignancies).

The "ATP Trap": A Technical Pitfall in Efficacy Assessment

A significant finding of this study is the discrepancy between standard metabolic assays and direct cell counting. Standard assays, such as CellTiter-Glo, measure ATP levels as a proxy for cell viability. However, CDK4/6 inhibition induces a senescence-like state where cells cease division but continue to grow in size and remain metabolically active.

Ribociclib-induced cell enlargement in SK-MEL-30 and NB1 cells compared to DMSO control.

As shown in the microscopy images, treated cells become significantly larger. These "giant" arrested cells produce substantial amounts of ATP, leading metabolic assays to report high viability even when the cell population has stopped expanding. Direct cell counting via high-content microscopy is necessary to accurately capture the potency of CDK4/6 inhibitors.

Biomarkers and Combination Strategies

The study identified RB1 (Retinoblastoma protein) loss as a primary biomarker for resistance; without functional RB1, the "brake" mechanism of CDK4/6 inhibition is effectively useless.

Beyond single-agent activity, ribociclib proved to be a potent "force multiplier" in combination therapies:

  • Melanoma: In BRAF-mutant models, combining ribociclib with the BRAF inhibitor encorafenib significantly delayed the emergence of resistance compared to monotherapy.
  • Lung Cancer: In EGFR-mutant NSCLC, adding ribociclib to the EGFR inhibitor nazartinib led to sustained tumor regression.
  • Breast Cancer: The combination of ribociclib and letrozole in HR+ breast cancer models produced deeper and more durable responses than either drug alone.

Conclusion

Ribociclib is a highly selective and potent CDK4/6 inhibitor with a favorable preclinical profile. Its efficacy is best captured by direct cell counting rather than metabolic assays, and its versatility as a combination partner across multiple cancer types underscores its clinical potential.

Summary updated

Abstract

Inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) is associated with robust antitumor activity. Ribociclib (LEE011) is an orally bioavailable CDK4/6 inhibitor that is approved for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer, in combination with an aromatase inhibitor, and is currently being evaluated in several additional trials. Here, we report the preclinical profile of ribociclib. When tested across a large panel of kinase active site binding assays, ribociclib and palbociclib were highly selective for CDK4, while abemaciclib showed affinity to several other kinases. Both ribociclib and abemaciclib showed slightly higher potency in <i>CDK4</i>-dependent cells than in <i>CDK6</i>-dependent cells, while palbociclib did not show such a difference. Profiling CDK4/6 inhibitors in large-scale cancer cell line screens <i>in vitro</i> confirmed that <i>RB1</i> loss of function is a negative predictor of sensitivity. We also found that routinely used cellular viability assays measuring adenosine triphosphate levels as a proxy for cell numbers underestimated the effects of CDK4/6 inhibition, which contrasts with assays that assess cell number more directly. Robust antitumor efficacy and combination benefit was detected when ribociclib was added to encorafenib, nazartinib, or endocrine therapies in patient-derived xenografts.
BibTeX
@inproceedings{kim2018potent,
  author = {Sunkyu Kim and Ralph Tiedt and Alice Loo and Thomas Horn and Scott Delach and Steven Kovats and Kristy Haas and Barbara Schacher Engstler and Alexander Cao and Maria Pinzon-Ortiz and Iain J. Mulford and Michael Acker and Rajiv Chopra and Christopher T. Brain and Emmanuelle di Tomaso and William R. Sellers and Giordano Caponigro},
  title = {{The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models}},
  booktitle = {Oncotarget},
  year = {2018},
  doi = {10.18632/oncotarget.26215},
}
Figure